Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis

By Jie Yang, M. Hughes, U. Kammula, R. Royal, R. Sherry, S. Topalian, K. B. Suri, Catherine L. Levy, T. Allen, S. Mavroukakis and 3 more. Journal of immunotherapy, 2007

703 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/3af955311049f4322a27b657535d889e49074149

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Immune Checkpoint Targeting in Cancer Therapy: Towards Combination Strategies with Curative Potential (2015, background): “Tumor regression was observed in phase I/II trials in patients with a variety of tumor types, including melanoma, renal cell carcinoma, prostate cancer, urothelial carcinoma, and ovarian cancer (Yang et al., 2007; Hodi et al., 2008; Carthon et al., 2010; van den Eertwegh et al., 2012).”
Immune checkpoint blockade: a common denominator approach to cancer therapy (2015, background): “In a phase II study of metastatic renal cell carcinoma (RCC, n = 61), a partial response rate of 10%was observedwith ipilimumab monotherapy (Yang et al., 2007).”
Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis (2015, background): “Yang [23] Randomized, double blind, phase II, dose ranging study Renal cell 61 Ipilimumab 1; 3 n/a”
Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells (2016, background): “(legend continued on next page) 1136 Immunity 45, 1135–1147, November 15, 2016 Hodi et al., 2010; van den Eertwegh et al., 2012; Yang et al., 2007).”
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma (2018, neutral): “Fatigue 202 (37) 23 (4) 264 (49) 49 (9)”
Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis (2017, background): “001) (Figure 2).(14-50) The predicted incidence of hypothyroidism ranged from 3.”
Management of toxicities of immune checkpoint inhibitors. (2016, result): “have been associated with a greater response and survival in some small studies.[52, 79, 80] A retrospective evaluation of 139 patients of ipilimumab given at varying doses also found irAEs to be predictive of response and survival and the highest response rate was seen in those who had grade 3 and ”